Azacitidine prolongs overall survival and reduces infections and hospitalizations in patients with WHO-defined acute myeloid leukaemia compared with conventional care regimens: an update

被引：11

作者：

Fenaux, P. ^{[1
]}

Mufti, G. J. ^{[2
]}

Hellstrom-Lindberg, E. ^{[3
]}

Santini, V. ^{[4
]}

Gattermann, N. ^{[5
]}

Sanz, G. ^{[6
]}

List, A. F. ^{[7
]}

Gore, S. D. ^{[8
]}

Seymour, J. F. ^{[9
]}

Backstrom, J. ^{[10
]}

Zimmerman, L. ^{[10
]}

McKenzie, D. ^{[10
]}

Beach, C. L. ^{[10
]}

Silverman, L. B. ^{[11
]}

机构：

[1] Univ Paris 13, Hop Avicenne, Bobigny, France

[2] Kings Coll London, Dept Haematol Med, London, England

[3] Karolinska Univ Hosp, Stockholm, Sweden

[4] Azienda Osped Careggi, Hematol, Florence, Italy

[5] Univ Dusseldorf, Dusseldorf, Germany

[6] Hosp Univ La Fe, Dept Hematol, Valencia, Spain

[7] H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA

[8] Johns Hopkins, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD USA

[9] Peter MacCallum Canc Inst, Dept Haematol, Melbourne, Vic, Australia

[10] Celgene, Overland Pk, KS USA

[11] Dana Farber Canc Inst, Pediat Oncol, Boston, MA 02115 USA

来源：

ECANCERMEDICALSCIENCE | 2008年 / 2卷

关键词：

D O I：

10.3332/ecancer.2008.121

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Azacitidine (AZA), as demonstrated in the phase III trial (AZA-001), is the first MDS treatment to significantly prolong overall survival (OS) in higher risk MDS pts ((2007) Blood 110 817). Approximately, one-third of the patients (pts) enrolled in AZA-001 were FAB RAEB-T (>= 20-30% blasts) and now meet the WHO criteria for acute myeloid leukaemia (AML) ((1999) Blood 17 3835). Considering the poor prognosis (median survival < 1 year) and the poor response to chemotherapy in these pts, this sub-group analysis evaluated the effects of AZA versus conventional care regimens (CCR) on OS and on response rates in pts with WHO AML.

引用

页数：3